Available online 11 April 2022, 101661
AbstractHashimoto’s thyroiditis (HT) and Graves’ disease (GD) are prevalent autoimmune disorders, representing opposite ends of the clinical spectrum of autoimmune thyroid diseases (AITD). The pathogenesis involves a complex interplay between environment and genes. Specific susceptibility genes have been discovered that predispose to AITD, including thyroid-specific and immune-regulatory genes. Growing evidence has revealed that genetic and epigenetic variants can alter autoantigen presentation during the development of immune tolerance, can enhance self-peptide binding to MHC (major histocompatibility complex), and can amplify stimulation of T- and B-cells. These gene-driven mechanistic discoveries lay the groundwork for novel treatment targets. This review summarizes recent advances in our understanding of key AITD susceptibility genes (Tg, TSHR, HLA-DR3, and CD40) and their translational therapeutic potential.
KeywordsAutoimmunity
Genes
Epigenetics
Hashimoto’s thyroiditis
Graves’ disease
thyroglobulin
CD40
HLA
MHC
View full text© 2022 Elsevier Ltd. All rights reserved.
留言 (0)